stuartlpbi | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Advertisements

Feeds:: Posts; Comments

About: Stuart Cantor

Website: http://stuartlpbi.wordpress.com
Details: I have a Ph.D. in pharmaceutical sciences and my expertise is in solid oral dosage formulation development and controlled-release technologies. I also have a deep background in intellectual property in the areas of chemistry, pharma, medical device, and biotech.

Posts by Stuart Cantor:

February 8, 2016 Bio-MEMS Technologies: Devices, Tissue Engineering & Drug Delivery, Presentation by Stuart Cantor, Ph.D. on 2/4/16

Advertisements

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,430 other followers
Recent Posts
- Digital Therapeutics: A threat or opportunity to pharmaceuticals March 18, 2019
- Immunoediting can be a constant defense in the cancer landscape March 16, 2019
- Immunotherapy may help in glioblastoma survival March 16, 2019
- 2018 CEO’s Compensation in Health Companies – Highest $99 Million to mid range $20 Million March 14, 2019
- Lesson 5 Cell Signaling And Motility: Cytoskeleton & Actin: Curations and Articles of reference as supplemental information: #TUBiol3373 March 13, 2019
- 2019 Koch Institute Symposium – Machine Learning and Cancer, June 14, 2019, 8:00 AM-5:00 PMET MIT Kresge Auditorium, 48 Massachusetts Ave, Cambridge, MA March 12, 2019
- Mitralign and Corvia, Tewksbury, Mass – Investment and Acquisition by Edwards Lifesciences March 11, 2019
- VIDEOS: Artificial Intelligence Applications for Cardiology March 11, 2019
- At California Central District Court Juno Therapeutics, Inc. et al v. Kite Pharma, Inc. – Multi-party Patent Infringement March 11, 2019
- Tips on 280 Character Tweets on Twitter.com March 10, 2019
Archives
Archives
Categories
Categories
Meta

Advertisements